Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
VRTX · Nasdaq · United States · Pharmaceutical Preparations
In shortVERTEX PHARMACEUTICALS INC / MA is profitable.
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 34.8% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 32.9% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 22.5% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.90× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 313.78× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 7.50 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 26.6% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.81× | 63/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 5.6% | 91/100 |
| Operating margin volatility | 19.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 10.4% | 74/100 |
|---|---|---|
| EPS growth, 3-year average | 6.1% | 56/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 |
| Cost of revenue | 904 | 1,080 | 1,262 | 1,531 | 1,651 |
| Gross profit | 6,670 | 7,850 | 8,607 | 9,490 | 10,350 |
| Research & development | 3,051 | 2,540 | 3,163 | 3,630 | 3,910 |
| Selling, general & admin | 840 | 945 | 1,137 | 1,464 | 1,753 |
| Operating income | 2,782 | 4,307 | 3,832 | (233) | 4,173 |
| Interest expense | – | 55 | 44 | 31 | 13 |
| Pre-tax income | 2,730 | 4,232 | 4,380 | 249 | 4,643 |
| Income tax | 388 | 910 | 760 | 784 | 690 |
| Net income | 2,342 | 3,322 | 3,620 | (536) | 3,953 |
| Diluted EPS | $9.01 | $12.82 | $13.89 | −$2.08 | $15.32 |
| Diluted shares (millions) | 260 | 259 | 261 | 258 | 258 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
7.50 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 4, 2026